InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
Affected assets and topics
Why it matters
FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence.
Article tone
Expected market reaction
Evidence trail
Evidence
AI provenance
Technical identifiers
- Provider tag
- huggingface-ProsusAI/finbert
- Analysis version
- huggingface-ProsusAI/finbert
- Article id
- 64011
- Timeframe
- 6h
Prediction lifecycle
-
FinBERT NASDAQ Neutral 94%Generated 6h Excluded
Expired: not evaluated within 7 days of its 6h timeframe elapsing
Logged at publication, scored automatically once the window closes — never edited.
Original source
Vancouver, British Columbia--(Newsfile Corp. - March 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors, today announced the Company received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") dated March 27, 2026, notifying it that the closing bid price of the Company's common shares...
Read the full article on Yahoo Finance
Original article published by Yahoo Finance on March 28, 2026. Analysis and insights provided by AnalystMarkets AI.